Centogene (CNTGF) has released an update.
Centogene’s shareholders have approved all resolutions at their Extraordinary General Meeting, including the anticipated sale of Centogene GmbH to Charme Capital Partners. This strategic move could potentially enhance Centogene’s focus on providing data-driven solutions for rare and neurodegenerative diseases, while aligning with growing interest from investors in precision medicine.
For further insights into CNTGF stock, check out TipRanks’ Stock Analysis page.